Ep 10: Insitro CEO Daphne Koller on Using ML to Change Drug Discovery

Jacob sits down with Insitro CEO Daphne Koller to discuss founding Coursera, where and how ML can drive the most impact in drug development, and if foundation models can transform core drug discovery work and edtech. 

 

(00:00) - intro 

(00:54) - Daphne’s journey 

(09:18) - AI and biology discovery 

(10:59) - insitro vs. traditional pharma 

(20:04) - phenotyping patients 

(26:01) - early mistakes 

(29:51) - the future of data 

(35:33) - partnering with larger pharma companies 

(38:17) - impact of LLMs on biopharma 

(44:04) - over-hyped/under-hyped 

 

With your co-hosts: 

@jasoncwarner - Former CTO GitHub, VP Eng Heroku & Canonical 

@ericabrescia - Former COO Github, Founder Bitnami (acq’d by VMWare) 

@patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn 

@jacobeffron - Partner at Redpoint, Former PM Flatiron Health

Jacob is an AI investor at Redpoint Ventures. He's led Redpoint's investments in companies like Abridge, Physical Intelligence & Legora. Follow Jacob on Twitter (@jacobeffron).

On Unsupervised Learning we probe the sharpest minds in AI in search for the truth about what's real today, what will be real in the future and what it all means for businesses and the world. If you're a builder, researcher or investor navigating the AI world, this podcast will help you deconstruct and understand the most important breakthroughs and see a clearer picture of reality. Subscribe to this show to stay up to date on our latest episodes.